Drugs / CART123 cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06768476 | Feb 2025 → Mar 2045 expected | acute myeloid leukemia | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04678336 | Apr 2021 → May 2025 | childhood acute myeloid leukemia | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1 | NCT03766126 | Dec 2018 → Mar 2026 | acute myeloid leukemia | University of Pennsylvania | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-123 cells | “The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting...” NCT03766126 ↗ |
| Modality | Cell therapy | “autologous anti-CD123 CAR T cells” PMID 39333315 ↗ Sep 2024 |
| Route | Intravenous | “intravenously administered” NCT03766126 ↗ |